An Azole-Tolerant Endosomal Trafficking Mutant of Candida albicans Is Susceptible to Azole Treatment in a Mouse Model of Vaginal Candidiasis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
We recently reported that a Candida albicans endosomal trafficking mutant continues to grow after treatment with the azole antifungals. Herein, we report that the vps21 Δ/Δ mutant does not have a survival advantage over wild-type isolates after fluconazole treatment in a mouse model of vaginal candidiasis. Furthermore, loss of VPS21 does not synergize with established mechanisms of azole resistance, such as overexpression of efflux pumps or of Erg11p, the target enzyme of the azoles. In summary, although loss of VPS21 function enhances C. albicans survival after azole treatment in vitro , it does not seem to affect azole susceptibility in vivo .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This recommendation is based upon studies of acute infections using the mouse model of bloodstream candidiasis 20 , and the observation that isolates with high trailing growth in mucosal infections respond positively to short-term antifungal treatment, despite later recurrence of infection 21 .”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612 · cited 2×
“of the target enzyme Erg11p, and of drug efflux pumps such as Cdr1p (1), Cdr2p (2), and Mdr1p 39”
BackgroundSanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587 · cited 2×
“of the target enzyme Erg11p, and of drug efflux pumps such as Cdr1p (1), Cdr2p (2), and Mdr1p 39”
BackgroundAntimicrobial Agents and Chemotherapy
(2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac · Cited by 485
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470 · cited 1×
“usually necessary to confer a significant increase in azole resistance (4).”
BackgroundResistance Mechanisms in Clinical Isolates of Candida albicans
White, T. C., Holleman, S., Dy, F., Mirels, L. F., & Stevens, D. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1704-1713.2002 · Cited by 461
Dunkel, N., Liu, T. T., Barker, K. S., Homayouni, R., Morschhäuser, J., & Rogers, P. D. (2008) · Eukaryotic Cell · doi:10.1128/ec.00103-08 · Cited by 236 · cited 1×
“In addition, overexpression of a gain-of-function UPC2G648D allele, encoding a transcription factor that enhances expression of the ergosterol biosynthetic genes (12) and known to confer partial azole resistance, reduced azole susceptibility of wild-type and vps21Δ/Δ mutant strains to a similar extent ( 4-fold) (data…”
BackgroundSelf-citationRex, J. H., Nelson, P. W., Paetznick, V. L., Lozano-Chiu, M., Espinel-Ingroff, A., & Anaissie, E. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.1.129 · Cited by 167 · cited 2×
“This can 51 make these isolates appear to be azole resistant (9, 10), although they are not typically associated 52 with antifungal treatment failure, and are therefore considered to be azole susceptible (11).”
BackgroundArthington-Skaggs, B. A., Lee-Yang, W., Ciblak, M. A., Frade, J. P., Brandt, M. E., Hajjeh, R. A., Harrison, L. H., Sofair, A. N., & Warnock, A. D. W. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2477-2481.2002 · Cited by 158 · cited 1×
“albicans clinical isolates with the standard CLSI broth 48 microdilution antifungal susceptibility testing protocol (7, 8).”
MethodArthington-Skaggs, B. A., Warnock, D. W., & Morrison, C. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2081-2085.2000 · Cited by 142 · cited 2×
“This can 51 make these isolates appear to be azole resistant (9, 10), although they are not typically associated 52 with antifungal treatment failure, and are therefore considered to be azole susceptible (11).”
BackgroundRevankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., & Patterson, T. F. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.1.153-156.1998 · Cited by 133 · cited 1×
“This can 51 make these isolates appear to be azole resistant (9, 10), although they are not typically associated 52 with antifungal treatment failure, and are therefore considered to be azole susceptible (11).”
Background
Research works printed but not linked: 1
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Rosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270
Van Dijck, P., Sjollema, J., Camue, B. P. A., Lagrou, K., Berman, J., d’Enfert, C., Andes, D. R., Arendrup, M. C., Brakhage, A. A., Calderone, R., et al. (2018) · Microbial Cell · doi:10.15698/mic2018.07.638 · Cited by 129
Bioactive Peptides Against Fungal Biofilms
Oshiro, K. G. N., Rodrigues, G. R., Monges, B. E. D., Cardoso, M. H. E. S., & Franco, O. L. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02169 · Cited by 92
Feng, Y., Lu, H., Whiteway, M., & Jiang, Y. (2023) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2023.10.019 · Cited by 40
The Vacuolar Ca 2+ ATPase Pump Pmc1p Is Required for Candida albicans Pathogenesis
Luna-Tapia, A., DeJarnette, C. A., Sansevere, E. A., Reitler, P., Butts, A., Hevener, K. E., & Palmer, G. E. (2019) · mSphere · doi:10.1128/msphere.00715-18 · Cited by 26
“In its extreme form, trailing growth can be mistaken for true azole resistance; however, patients and experimental animals infected with trailing isolates generally respond well to treatment with the azoles (36, 37).”
Self-citation
Metadata
- Authors
- Peters, B. M., Luna-Tapia, A., Tournu, H., Rybak, J. M., Rogers, P. D., & Palmer, G. E.
- Affiliations
- University of Tennessee Health Science Center (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2017-06
- Volume
- 61
- Issue
- 6
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5444139
- OpenAlex
- W2602359364
- Cited by
- 12
- References
- 11
- Citations by year
- 2023: 1 · 2022: 2 · 2021: 3 · 2019: 2 · 2018: 3 · 2017: 1
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Repositorio Institucional Universidad de Sucre (submittedVersion, cc-by-nc)
- Funders
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI099080, K22AI110541, R01AI058145)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, azole resistance, endosomal trafficking, fluconazole susceptibility, vaginal candidiasis, efflux pumps, antifungal susceptibility, mouse model
- MeSH terms
- Animals, Antifungal Agents, Candida albicans, Candidiasis, Vulvovaginal, Disease Models, Animal, Female, Mice, Inbred C57BL, Microbial Sensitivity Tests, Fluconazole, rab GTP-Binding Proteins, Drug Resistance, Fungal, Membrane Transport Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Azole-Tolerant Endosomal Trafficking Mutant of Candida albicans Is Susceptible to Azole Treatment in a Mouse Model of Vaginal Candidiasis. https://app.cochat.ai/papers/10.1128/aac.00084-17
- The paper
- Peters, B. M., Luna-Tapia, A., Tournu, H., Rybak, J. M., Rogers, P. D., & Palmer, G. E. (2017). An Azole-Tolerant Endosomal Trafficking Mutant of Candida albicans Is Susceptible to Azole Treatment in a Mouse Model of Vaginal Candidiasis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00084-17
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.